EMEA-002010-PIP01-16-M03 - paediatric investigation plan

Axicabtagene ciloleucel

Key facts

• Invented name:
  Yescarta
• Active Substance:
  Axicabtagene ciloleucel
• Therapeutic area:
  Oncology
• Decision number:
  P/0114/2022
• PIP number:
  EMEA-002010-PIP01-16-M03
• Pharmaceutical form(s):
  Dispersion for infusion
• Condition(s) / indication(s):
  Treatment of mature B-cell neoplasms
• Route(s) of administration:
  Intravenous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  13/04/2022

Decision

P/0114/2022 - Decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for axicabtagene ciloleucel (Yescarta), (EMEA-002010-PIP01-16-M03)

AdoptedReference Number: P/0114/2022